Kalamazoo, Michigan, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today it has completed the acquisition of Arrinex, Inc., a medical device company headquartered in Menlo Park, California, that has developed ClariFix®, a novel cryoablation technology for the treatment of chronic rhinitis. This condition, which affects over 24 million people in the U.S. each year, may cause runny nose, congestion, sneezing and nasal itching. Arrinex, which was founded in 2013, began commercializing ClariFix in late 2017 in the U.S. ClariFix further expands Stryker’s Ear, Nose and Throat (ENT) portfolio with a unique product to address a large, underpenetrated segment of the ENT market where Stryker does not currently compete.
“The acquisition of Arrinex is highly complementary to Stryker’s ENT portfolio, which is part of our Neurotechnology business,” said Spencer Stiles, Stryker’s Group President, Neurotechnology, Instruments and Spine. “This acquisition aligns with our focus on providing ENT physicians with new technologies that deliver more treatment options and better patient outcomes.”
Quest Imaging Solutions provides all major brands of surgical c-arms (new and refurbished) and carries a large inventory for purchase or rent. With over 20 years in the medical equipment business we can help you fulfill your equipment needs